$ASNS

ACTELIS NETWORKS INC (ASNS): Results of Operations and Financial Condition

ACTELIS NETWORKS INC (ASNS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Actelis Networks Reports Second Quarter 2026 Financial Results and Provides Business Update Revenues were up 20% year over year, reaching $1.1 million in the second quarter of 2026; gross margin was 51%, compared to 32% in the second quarter of 2025 New wins across I

Original reporting
Published Aug 13, 2026, 9:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 9:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ASNS
Bullish
medium confidence
Mentioned
$ASNS
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ASNSBullishMed
01

Why it matters

Traders can reassess near-term fundamentals (revenue growth, gross margin expansion) alongside capital-market risk (reverse split authorization and amended equity line capacity) that may affect share count and liquidity.

02

Market read

Company-specific earnings-style update with hard numbers (revenue and gross margin) plus capital-structure and relisting mechanics that can drive microcap volatility.

03

What to watch

The excerpt mentions an amended equity line up to $30M and a reverse split authorization, but does not quantify expected drawdown, cash runway, or dilution per share, which are key for trading the stock.

Relevance 7/10Novelty 7/10Timing: after-hours filing on Aug 13, 2026

Background

This is an SEC 8-K with an attached press release covering Actelis Networks’ Q2 2026 results and business update, including steps toward a Nasdaq relisting.

Company-level read

Ticker impact

$ASNSBullishMedium confidence
Context

Actelis reported Q2 2026 revenue of $1.1M (+20% YoY) and gross margin expansion to 51%, plus a reverse split plan and amended $30M equity line.

Expected impact

Near-term bias modestly positive on margin/revenue improvement, but volatility risk remains due to OTCQB trading context and potential dilution from the equity line.

Evidence & confidence

The filing provides fresh, company-specific datapoints (revenue, gross margin, cost actions, equity line amendment, reverse split authorization). However, it does not include full cash flow, guidance, or balance-sheet details in the provided excerpt, limiting conviction on valuation and dilution impact.

Market effects

Signals demand tailwinds for cyber-hardened IoT and networking tied to EU Cyber Resilience Act readiness, potentially supportive for similar networking/security vendors.

Highlights North America and EMEA revenue growth, suggesting continued regional traction rather than a single-market rebound.

Limited broader index impact, but reinforces ongoing modernization spending themes in transportation and telecom infrastructure.

Counterpoint

Gross margin improvement may partly reflect mix and cost actions, which could be harder to sustain if FX pressure and OTC liquidity conditions worsen.

Key entities

  • Actelis Networks, Inc.

    OTCQB-listed networking solutions provider reporting Q2 2026 results and relisting-related corporate actions.

  • Exaware Routing Ltd.

    Entered into an MoU with Actelis to preserve collaboration across data center, telecom, and critical infrastructure markets.

  • EU Cyber Resilience Act (CRA)

    Actelis cites it as a tailwind for cyber-hardening upgrades and related services.

Related articles

$CEROHighAI 8/10

Delisting of Securities from The Nasdaq Stock Market

Nasdaq said it will delist multiple issuers’ securities from the Nasdaq Stock Market, including CERo Therapeutics Holdings, Bowen Acquisition Corp, Graphjet Technology, Blue Hat Interactive Entertainment Technology, X3 Holdings Co, Captivision Inc, Actelis Networks, American Rebel Holdings, Reviva Pharmaceuticals, Alchemy Investments Acquisition Corp 1, Bitcoin Depot, Inotiv, GoHealth, Functional Brands, Sleep Number, Smart Digital Group, and REE Automotive. Most were suspended in 2025-2026 and

$TSLAHighAI 9/10

Tesla Posted Negative $1.1 Billion in Free Cash Flow Last Quarter as Elon Musk Ramps Up Spending on Robotaxis and Optimus. Here's Why the Company's $43.5 Billion Cash Cushion Still Matters.

Tesla reported a 26% revenue increase to $22.5B in Q2, with net income of $1.11B, but negative free cash flow of $1.1B due to $5.79B in capital expenditures. The company's $43.5B cash position provides a buffer for growth investments in robotaxis, Optimus robots, and semiconductors. Tesla's market share in U.S. EVs has risen despite industry contraction, but competition from Chinese rivals like BYD persists.

$BWINMed

Michael Dell Just Made a $7.7 Billion Bet on This Insurance Stock

Michael Dell is acquiring Baldwin & Co. (BWIN) for $7.7B. Baldwin reported Q2 revenue of $492.9M (+30% YoY), adjusted net income of $68.5M, and adjusted EBITDA of $116.7M (+37%). Management guided Q3 revenue to $485M-$495M and full-year revenue to $2.01B-$2.05B. Analysts have mixed targets, with a consensus 'Moderate Buy' and average target of $33.

$AMZNMedAI 8/10

Should You Buy Amazon Stock For The Demand AWS Cannot Yet Serve?

Amazon.com (AMZN) stock is down 13% from its 52-week high, despite AWS's 36.7% YOY revenue growth in Q2 2026. AWS's backlog of committed contracts reached $496 billion, with demand outpacing capacity. AWS's operating margin improved 520 basis points YOY, excluding energy contract gains. Management attributes growth to AI workloads and efficient capacity use.

$ASMLMedAI 8/10

Weakness Is an Opportunity for Long-Term ASML Stock Investors

ASML's High-NA technology is gaining traction among chipmakers like Samsung, Intel, and TSMC, crucial for its long-term outlook. Q2 earnings beat estimates with €7.59 EPS and €9.33B revenue. ASML raised full-year 2026 sales guidance to €43B-€45B. Analysts have a consensus 'Hold' rating, with a mean price target of $2,350.75, implying 56% upside.